Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property
Restricted accessResearch articleFirst published online June, 2013
Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property
This study investigates the beneficial role of lisinopril, an angiotensin converting enzyme inhibitor (ACEI) and telmisartan, an angiotensin receptor blocker (ARB), in intracerebroventricular (i.c.v.) streptozotocin (STZ) induced dementia of Alzheimer’s disease (AD) type in mice. This study also aimed to explore the role of PPAR-γ in lisinopril and telmisartan mediated effects in i.c.v. STZ mice. Donepezil served as the positive control in the study. Mice underwent i.c.v. injection of STZ. The Morris water maze (MWM) test was employed for assessment of learning and memory. Various biochemical estimations, namely brain acetylcholinesterase (AChE) activity, myeloperoxidase (MPO) activity, nitrite/nitrate and thiobarbituric acid reactive species (TBARS) levels and reduced glutathione (GSH) levels, were also performed. The study showed that i.c.v. STZ significantly impaired learning and memory of the animals along with a significant enhancement in brain AChE, MPO, TBARS, nitrite/nitrate levels and reduction in brain GSH levels. Treatments of lisinopril/telmisartan/donepezil significantly attenuated STZ induced behavioral and biochemical changes. Pre-treatment with bisphenol-A-diglycidyl ether (BADGE), a selective PPAR-γ antagonist, significantly abolished the beneficial effect of lisinopril/telmisartan in i.c.v. STZ treated animals. The results of this investigation document a potential role of PPAR-γ in the beneficial effects of lisinopril and telmisartan in i.c.v. STZ dementia of AD type.
CitronM. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov2010; 9: 387–398.
6.
HampelHFrankRBroichK. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov2010; 9: 560–574.
7.
CagnoniFNjweCAZaninelliA. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag2010; 6: 549–559.
8.
KehoePGWilcockGK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease?Lancet Neurol2007; 6: 373–378.
9.
CiobicaABildWHritcuL. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg2009; 109: 171–180.
10.
LiNCLeeAWhitmerRA. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ2010; 340: b5465.
11.
YamadaKUchidaSTakahashiS. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res2010; 1352: 176–186.
12.
HajjarIMKeownMLewisP. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer’s disease: an observational study. Am J Alzheimers Dis Other Demen2008; 23; 77–83.
13.
HoriuchiMMogiM. Roles of activation of angiotensin II receptor subtypes in ischemic brain damage and cognitive function. Br J Pharmacol2011; 163: 1122–1130.
14.
ZouKYamaguchiHAkatsuH. Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition. J Neurosci2007; 27: 8628–8635.
15.
SharmaBSinghNSinghM. Modulation of celecoxib and streptozotocin-induced experimental dementia of Alzheimer’s disease type by pitavastatin and donepezil. J Psychopharmacol2008; 22: 162–171.
16.
SharmaBSinghNJaggiAS. Exploration of HIV protease inhibitor indinavir as a memory restorative agent in experimental induced dementia. Pharmacol Biochem Behav2008; 89: 535–545.
17.
BlancoAAlvarezSFresnoM. Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner. J Alzheimers Dis2010; 22: 493–505.
18.
KaurBSinghNJaggiAS. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol2009; 23: 557–566.
19.
EscribanoLSimónAMGimenoE. Telmisartan rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology2010; 35: 1593–1604.
20.
LandrethGJiangQMandrekarS. PPAR gamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics2008; 5: 481–489.
21.
KaundalRKSharmaSS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect2010; 23: 241–256.
22.
NapolitanoMCostaLPalermoR. Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington’s disease. Brain Res Bull2011; 85: 231–237.
23.
FouadAAAl-SultanAIYacoubiMT. Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration. Eur J Pharmacol2010; 637: 162–170.
24.
JermendyG. Is type-2 diabetes mellitus preventable?Orv Hetil2003;144: 1909–1917.
25.
HamedAAMalekHA. Effect of telmisartan in experimentally induced diabetetes mellitus in rats. Int J Health Sci (Qassim)2007; 1: 249–256.
26.
MatsumuraTKinoshitaHIshiiN. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-{gamma} in macrophages. Arterioscler Thromb Vasc Biol2011; 31: 1268–1275.
27.
LakshmananAPWatanabeKThandavarayanRA. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res2011; 45: 575–584.
28.
MorrisRGM. Development of a water maze producer for studying spatial learning in the rats. J Neurosci Meth1984; 11: 47–60.
29.
SharmaBSinghN. Pitavastatin and 4′-hydroxy-3′-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr Neurovasc Res2010; 7: 180–191.
30.
EllmanGLCourtneyDKAndresV. A new and rapid colorimeteric determination of acetylcholinesterase activity. Biochem Pharmacol1961; 7: 88–95.
31.
VossGSachsseK. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylcholine/DTNB procedure. Toxicol Appl Pharmacol1970; 16: 764–772.
32.
GreenLCWagnerDAGlogowskiJ. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem1982; 126: 131–138.
33.
GrishamMBBenoitJNGrangerDN. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol1990; 186: 729–742.
34.
OhokawaHOhishiNYagiK. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem1979; 95: 351–358.
35.
BeutlerEDuronOKellyB. Improved method for the determination of blood glutathione. J Lab Clinical Med1963; 61: 882–888.
36.
LowryOHRosebroughNJFarAL. Protein measurement with folin-phenol reagent. J Biol Chem1951; 193: 265–275.
37.
HouDWangYZhouL. Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease. Chin Med J2008; 121: 2320–2323.
38.
TsukudaKMogiMIwanamiJ. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension2009; 54: 782–787.
39.
MogiMLiJMTsukudaK. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008; 375: 446–449.
40.
ZhangSLYangXJLiuTF. Effect and mechanism of jiannao yizhi decoction on learning and memory in rats with similar Alzheimer’s disease. Zhongguo Zhong Xi Yi Jie He Za Zhi2008; 28: 529–531.
41.
RinwaPKaurBJaggiAS. Involvement of PPAR-gamma in curcumin-mediated beneficial effects in experimental dementia. Naunyn Schmiedebergs Arch Pharmacol2010; 381: 529–539.
42.
ParleMSinghN. Reversal of memory deficits by atorvastatin and simvastatin in rats. Yakugaku Zasshi2007; 127: 1125–1137.
43.
PackardMGTeatherLABazanNG. Effect of intra-striated injectins of platelet-activating factor and PAF antagonist BN 52021 on memory. Neurobiol Learn Mem1996; 66: 176–182.
44.
CamarasaJRodrigoTPubillD. Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res2010; 62: 450–456.
45.
TotaSAwasthiHKamatPK. Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res2010; 209: 73–79.
46.
LannertHHoyerS. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci1998; 112: 1199–1208.
47.
MayerGNitschRHoyerS. Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. Brain Res1990; 532: 95–100.
48.
HoyerSMullerDPlaschkeK. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm1994; 44: S259–S268.
49.
HoyerS. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late onset sporadic Alzheimer’s disease (SAD). A mini review. J Neural Transm2000; 109: 991–1002.
50.
HoyerS. The brain insulin signal transduction system and sporadic (type II) Alzheimer’ s disease: an update. J Neural Transm2000; 109: S341–S360.
51.
AgrawalRTyagiEShuklaR. A Study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology2009; 56: 779–787.
52.
ShohamSBejarCKovalevE. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol2003; 184: 1043–1052.
53.
GrünblattEKoutsilieriEHoyerS. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis2006; 9: 261–271.
54.
CerielloAQuagliaroLD’AmicoM. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes2002; 51: 1076–1082.
55.
SpitalerMMGraierWF. Vascular targets of redox signalling in diabetes mellitus. Diabetologia2002; 45: 476–494.
56.
KumaranDUdayabanuMKumarM. Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience2008; 155: 626–639.
57.
SavaskanE. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res2005; 2: 29–35.
58.
SukhanovSSemprun-PrietoLYoshidaT. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci2011; 342: 143–147.
59.
KimJMUeharaYChoiYJ. Mechanism of attenuation of pro-inflammatory Ang II-induced NF-κB activation by genistein in the kidneys of male rats during aging. Biogerontology2011; 12: 537–550.
60.
YasarSZhouJVaradhanR. The use of angiotensin-converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women. Clin Pharmacol Ther2008; 84: 119–126.
61.
BarnesJMBarnesNMCostallB. Angiotensin II inhibits the release of [3H] acetylcholine from rat entorhinal cortex in vitro. Brain Res1989; 491: 136–143.
62.
BarnesJMBarnesNMCostallB. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res1990; 507: 341–343.
63.
YaffeKLindquistKPenninxBW. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology2003; 61: 76–80.
64.
TuppoEEAriasHR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol2005; 37: 289–305.
65.
HaraguchiTTakasakiKNaitoT. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Neurosci Lett2009; 464: 151–155.
66.
IsmailHMitchellRMcFarlaneSI. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep2010; 10: 32–36.
67.
KasaharaYTaguchiAUnoH. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res2010; 1340: 70–80.
68.
HwangSJKimJHShimJW. Peroxisome proliferator-activated receptor-gamma expression in the lung tissue of obese rats. Yonsei Med J2011; 52: 495–501.
69.
OhruiTMatsuiTYamayaM. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer’s disease in Japan. J Am Geriatr Soc2004; 52: 649–650.
70.
TanJWangJMLeenenFH. Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens2005; 18: 158–164.
71.
WyssJMKadishIVan GroenT. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens2003; 25: 455–474.
72.
HaraguchiTIwasakiKTakasakiK. Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. Brain Res2010; 1353: 125–132.
73.
KuriharaTOzawaYShinodaK. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci2006; 47: 5545–5552.
74.
KobayashiTKawamataTShibataN. Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A (2) level in experimental stroke. J Neurotrauma2009; 26: 2355–2364.
75.
JungKHChuKLeeST. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther2007; 322: 1051–1058.
76.
AhmedTGilaniAH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease. Pharmacol Biochem Behav2009; 91: 554–559.
77.
HajjarIHartMMilbergW. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr2009; 9: 48.
78.
AndersonCTeoKGaoP. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol2011; 10: 43–53.
79.
Fatehi-HassanabadZTaskerRA. Peroxisome proliferator-activated receptors-gamma PPAR-gamma) activation confers functional neuroprotection in global ischemia. Neurotox Res2011; 19: 462–471.
80.
GlatzTStockINguyen-NgocM. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischemic brain. J Hypertens2010; 28: 1488–1497.
81.
PereiraMPHurtadoOCárdenasA. Telmisartan and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab2006; 26: 218–229.
82.
HyongAJadhavVLeeS. Telmisartan, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res2008; 1215: 218–224.
83.
ZhaoXStrongRZhangJ. Neuronal PPAR gamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci2009; 29: 6186–6195.
84.
NicolakakisNAboulkassimTOngaliB. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci2008; 28: 9287–9296.
85.
HalvorsenBHeggenEUelandT. Treatment with the PPAR gamma agonist telmisartan downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol2010; 162: 267–273.
86.
ZhangQHuWMengB. PPARgamma agonist telmisartan is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res2010; PMID: 20350367.
87.
LandrethG. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer’s disease. Curr Alzheimer Res2007; 4: 159–164.
88.
SodhiRKSinghNJaggiAS. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer’s disease. Naunyn Schmiedebergs Arch Pharmacol2011; 384: 115–124.
89.
ToledoEMInestrosaNC. Activation of Wnt signaling by lithium and telmisartan reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry2010; 15: 272–285.
90.
DongHYuedeCMCoughlanCA. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer’s disease. Brain Res2009; 1303: 169–178.
91.
MaelickeAHoeffle-MaasALudwigJ. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci2010; 40: 135–137.
